相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway
Xiaozhen Liu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Yen-Hsiang Huang et al.
CANCER RESEARCH AND TREATMENT (2018)
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Chia-Chi Lin et al.
LANCET RESPIRATORY MEDICINE (2018)
The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer
Mona Alharbi et al.
ENDOCRINE-RELATED CANCER (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
V A Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2018)
Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer
Yan Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner
Xiaobing Qin et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
Yuan Gao et al.
BMC CANCER (2017)
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Dana S. Neel et al.
NPJ PRECISION ONCOLOGY (2017)
The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor
Cara J. Valvona et al.
BRAIN PATHOLOGY (2016)
Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222
Dan-dan Yu et al.
TUMOR BIOLOGY (2016)
Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis
Xiuxiu Zhang et al.
CANCER BIOMARKERS (2016)
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Sandra Ortiz-Cuaran et al.
CLINICAL CANCER RESEARCH (2016)
Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer
Seok-Hyun Kim et al.
ONCOTARGET (2016)
Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis
Hua Zhang et al.
SCIENTIFIC REPORTS (2016)
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance
Roberta Minari et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D. Planchard et al.
ANNALS OF ONCOLOGY (2015)
Signaling by exosomal microRNAs in cancer
Germana Falcone et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Overexpression of CRM1 A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy
Weimin Gao et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor
Tae Min Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)
Nesaretnam Barr Kumarakulasinghe et al.
RESPIROLOGY (2015)
Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular Vesicles
Diana Sousa et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study
Yuankai Shi et al.
PLOS ONE (2015)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Cell-Cell Communication between Malaria-Infected Red Blood Cells via Exosome-like Vesicles
Neta Regev-Rudzki et al.
CELL (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy
Kenneth K. W. To
JOURNAL OF BIOMEDICAL SCIENCE (2013)
Classification, Functions, and Clinical Relevance of Extracellular Vesicles
Edwin van der Pol et al.
PHARMACOLOGICAL REVIEWS (2012)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Exosome function: From tumor immunology to pathogen biology
Jeffrey S. Schorey et al.
TRAFFIC (2008)
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells
Hadi Valadi et al.
NATURE CELL BIOLOGY (2007)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
T Takano et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
